Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages 3723-3728

  Roboz, Gail J ^a   Ritchie, Ellen K ^a   Carlin, Rebecca F ^d   Samuel, Michael ^b   Gale, Leanne ^e   Provenzano Gober, Juliette L ^c   Curcio, Tania J ^a   Feldman, Eric J ^a   Kligfield, Paul D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d GREATER BALTIMORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; MAGNESIUM; POTASSIUM; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; POTASSIUM BLOOD LEVEL; PREVALENCE; QT INTERVAL; QT PROLONGATION; DRUG EFFECTS; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDES; PREVALENCE;

EID: 84911420075     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2913     Document Type: Article

References (27)

1. Lengfelder E, Hofmann WK, Nowak D: Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 26:433-442, 2012
2. Powell BL, Moser B, Stock W, et al: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010
3. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121, 2013
4. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
5. Goldsmith S, From AH: Arsenic-induced atypical ventricular tachycardia. N Engl J Med 303:1096-1098, 1980
6. Chiang CE, Luk HN, Wang TM, et al: Prolongation of cardiac repolarization by arsenic trioxide. Blood 100:2249-2252, 2002
7. Barbey JT, Pezzullo JC, Soignet SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615, 2003
8. Roboz GJ, Ritchie EK, Curcio T, et al: Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 113:2504-2511, 2008
9. Roboz GJ, Ritchie EK, Curcio T, et al: Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res 35:522-525, 2011
10. Kligfield P, Gettes LS, Bailey JJ, et al: Recommendations for the standardization and interpretation of the electrocardiogram: Part I. The electrocardiogram and its technology-A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 115:1306-1324, 2007
11. Kligfield P, Hancock EW, Helfenbein ED, et al: Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol 98:88-92, 2006
12. Kligfield P, Tyl B, Maarek M, et al: Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes. Ann Noninvasive Electrocardiol 12:145-152, 2007
13. Hnatkova K, Gang Y, Batchvarov VN, et al: Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol 29:1277-1284, 2006
14. Davey P: How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods 48:3-9, 2002
15. Chiladakis J, Kalogeropoulos A, Arvanitis P, et al: Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 21:905-913, 2010
16. Bazett HC: An analysis of time relations of electrocardiograms. Heart 7:353-370, 1920
17. Fridericia LS: Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 53:469-486, 1920
18. Hodges M, Salerno D, Erlien D: Bazett's QT correction reviewed: Evidence that a linear QT correction for heart rate is better. J Am Coll Cardiol 1:694, 1983
19. Sagie A, Larson MG, Goldberg RJ, et al: An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70:797-801, 1992
20. Douer D, Tallman MS: Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396-2410, 2005
21. Kligfield P, Green CL, Mortara J, et al: The Cardiac Safety Research Consortium electrocardiogram warehouse: Thorough QT database specifications and principles of use for algorithm development and testing. Am Heart J 160:1023-1028, 2010
22. Ohnishi K, Yoshida H, Shigeno K, et al: Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885, 2000
23. Harris RI, Steare SE: A meta-analysis of ECG data from healthy male volunteers: Diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies. Eur J Clin Pharmacol 62:893-903, 2006
24. Molnar J, Zhang F, Weiss J, et al: Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 27:76-83, 1996
25. Extramiana F, Maison-Blanche P, Badilini F, et al: Circadian modulation of QT rate dependence in healthy volunteers: Gender and age differences. J Electrocardiol 32:33-43, 1999
26. Malik M, Hnatkova K, Schmidt A, et al: Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 5:1424-1431, 2008
27. Drew BJ, Ackerman MJ, Funk M, et al: Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 121:1047-1060, 2010